MediWound Showcases Superior EscharEx Debridement Data Over SANTYL, Supports Phase III
MediWound will present new preclinical and clinical data demonstrating EscharEx’s superior debridement versus SANTYL, targeted molecular pathway activation, and improved scar outcomes at WHS, SAWC and EWMA conferences. The findings underpin its ongoing Phase III VALUE trial in venous leg ulcers and planned diabetic foot and pressure ulcer expansions.
1. Conference Presentations
MediWound will present multiple oral and poster sessions at the Wound Healing Society, Symposium on Advanced Wound Care Spring and European Wound Management Association meetings. These presentations focus on preclinical mechanism studies and clinical performance data supporting EscharEx’s next-generation enzymatic debridement role.
2. Key Data Highlights
New mechanistic studies demonstrate superior removal of nonviable tissue and activation of wound-healing pathways compared to the leading enzymatic agent. Clinical analyses reveal improved long-term scar outcomes, faster time to wound closure in VLUs, and post-hoc support from the ChronEx Phase II trial for the VALUE study’s co-primary endpoints.
3. Development Pathway
The global Phase III VALUE trial in venous leg ulcers is underway, with statistical assumptions bolstered by new data. MediWound plans to initiate clinical studies in diabetic foot and pressure ulcers in the second half of 2026, aiming to expand EscharEx’s indications and address a substantial chronic wound market.